Lenvatinib/lenvatinib (Lenvima) standard usage and dosage guidelines

Judging from the instructions and clinical application consensus, the usage and dosage design of Lenvatinib fully reflects the principle of “adjustment according to disease type and individual differences”. As monotherapy, the recommended dose of lenvatinib in differentiated thyroid cancer is 24 mg orally once daily, which is a standard regimen based on the disease's high dependence on angiogenesis and multi-target signaling pathways. For patients with hepatocellular carcinoma, the dose is closely related to body weight. Patients weighing no less than 60 kilograms are usually recommended to take 12 mg once a day, while patients weighing less than 60 kilograms are recommended to take 8 mg once a day. This layered dosing method helps to ensure the efficacy while reducing the risk of adverse reactions.

In combination treatment regimens, the dosing strategy of lenvatinib is more flexible. Taking endometrial cancer as an example, it is often used in combination with pembrolizumab. The recommended dose of lenvatinib is 20 mg orally once daily, while immunotherapy drugs are administered intravenously at established cycles. The core goal of this combined model is to improve the stability of disease control through the synergistic effect of targeted inhibition and immune activation. In the treatment of renal cell carcinoma, lenvatinib can be combined with either pembrolizumab or everolimus. The doses of lenvatinib corresponding to different combinations are slightly different, reflecting the emphasis on safety and tolerability in treatment guidelines.

It is worth noting that the dose of lenvatinib is not static regardless of whether it is single agent or combination therapy. For patients with impaired hepatic or renal function, guidelines generally recommend dose adjustments during initiation or during treatment to avoid the risk of drug accumulation in the body. This "dynamic management" medication concept is also an important feature that distinguishes modern targeted therapy from traditional chemotherapy.

Reference materials:https://www.lenvima.com/